Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000
- PMID: 11075414
Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000
Abstract
Background and objectives: The Swiss HIV Cohort Study (SHCS) was initiated in 1988 and represented the main scientific component of the comprehensive response to the AIDS epidemic in Switzerland. It brought together physicians and scientists from five university hospitals (Basel, Berne, Geneva, Lausanne and Zurich) and two Cantonal hospitals (Lugano and St. Gallen). The objective of SHCS was, and still is, to produce rapid, high quality patient-oriented medical research in the field of HIV infection.
Methods: SHCS is a prospective population-based cohort study. Any HIV-infected person aged > or = 16 years is eligible to participate. Data collection and study procedures are standardised. Data quality and protocol monitoring are conducted at the coordination and data centre in Lausanne. Detailed information on demographics, income, mode of HIV acquisition, risk behaviours, clinical events, laboratory results, treatment and treatment tolerance is collected at registration and at 6-monthly intervals.
Results: Since 1996, 10,600 persons have been enrolled and the SHCS study population is considered fairly representative of the HIV-infected population in Switzerland, at least in terms of gender and mode of HIV acquisition. In 1999, 4600 patients were actively followed up and more than 70% of patients were receiving highly active antiretroviral therapy (HAART). As a consequence, mortality and the incidence of HIV-related opportunistic infections have decreased significantly in the recent past. Between 1996 and 2000, 91 original manuscripts have been published by SHCS scientists and physicians, almost exclusively in peer-reviewed journals. A wide range of scientific questions have been addressed, including HIV primary infection, the natural history of HIV infection, the clinical and biological impact of HAART, drug resistance, risk factors for disease evolution including the timing of treatment initiation, the role of CD4 receptors, the validity of HIV surveillance reports, determinants of treatment access and tolerance, clinical trials of new drug combinations, the interruption of prophylaxis following a favourable response to HAART and issues relating to quality of life and interaction between income, social level and disease evolution.
Conclusion: The SHCS has had, and continues to have, a significant impact on medical practice, public health and research in Switzerland and beyond. It represents a network of excellence which has brought together and fostered intensive collaboration between physicians and institutions throughout this country and beyond. This was possible thanks to the support of the Federal Office of Public Health and the commitment of primary care physicians, researchers and patients. This project may be model for focused and prioritised multicentre and transdisciplinary research programmes.
Similar articles
-
[The Swiss HIV Cohort Study--a link between clinical research and medical practice].Ther Umsch. 1998 May;55(5):329-34. Ther Umsch. 1998. PMID: 9643131 German.
-
[Cause of death and autopsy findings in patients of the Swiss HIV Cohort Study (SHCS)].Schweiz Med Wochenschr. 2000 Nov 11;130(45):1726-33. Schweiz Med Wochenschr. 2000. PMID: 11109604 German.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.J Natl Cancer Inst. 2005 Mar 16;97(6):425-32. doi: 10.1093/jnci/dji072. J Natl Cancer Inst. 2005. PMID: 15770006
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
Cited by
-
Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies.Epidemiology. 2009 Sep;20(5):664-72. doi: 10.1097/EDE.0b013e3181a71519. Epidemiology. 2009. PMID: 19478669 Free PMC article.
-
IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients.AIDS. 2019 Sep 1;33(11):1719-1727. doi: 10.1097/QAD.0000000000002283. AIDS. 2019. PMID: 31225812 Free PMC article.
-
Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.AIDS Res Hum Retroviruses. 2010 Nov;26(11):1239-46. doi: 10.1089/aid.2010.0070. Epub 2010 Oct 7. AIDS Res Hum Retroviruses. 2010. PMID: 20929393 Free PMC article.
-
CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland.J Infect Dis. 2009 Dec 1;200(11):1729-35. doi: 10.1086/648096. J Infect Dis. 2009. PMID: 19848608 Free PMC article.
-
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.PLoS Med. 2008 Jul 8;5(7):e148. doi: 10.1371/journal.pmed.0050148. PLoS Med. 2008. PMID: 18613745 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials
Miscellaneous